PMID- 24202958
OWN - NLM
STAT- MEDLINE
DCOM- 20150127
LR  - 20231213
IS  - 1573-2584 (Electronic)
IS  - 0301-1623 (Linking)
VI  - 46
IP  - 5
DP  - 2014 May
TI  - Immunosuppressive effect of renal cell carcinoma on phenotype and function of 
      dendritic cells.
PG  - 915-20
LID - 10.1007/s11255-013-0595-8 [doi]
AB  - Dendritic cells (DCs) play an important role in anti-renal cell carcinoma (RCC) 
      immunity. The aim of the study was to investigate effect of mimic RCC 
      microenvironment on phenotype and function of DCs. We isolated conditioned media 
      (CM) from supernatants of culturing RCC cells and adjacent non-RCC cells in 
      patients. CD14+ monocytes were obtained from healthy donors. The monocytes 
      derived DCs were treated by RCC CM and non-RCC CM. Maturation markers CD80, CD83, 
      CD86, and HLA-DR on DCs were analyzed using flow cytometry, while the levels of 
      IL-10, TGF-beta, and IL12p70 in supernatants were examined by ELISA. The DCs 
      migration treated with RCC CM and non-RCC CM was investigated using transwell 
      assay. The DCs treated and allogenic T cells were co-cultured for detecting 
      T-cell proliferation and change of phenotype on the T cells. Our results 
      indicated that RCC CM inhibited the up-regulation of CD80,CD83, CD86, and HLA-DR 
      in response to LPS in treated DCs and increased IL-10 and TGF-beta secretion but 
      reduced IL12p70 production. Moreover, the migration ability of DCs treated with 
      RCC CM was also inhibited, compared to DCs treated with adjacent non-RCC CM. In 
      addition, T-cell proliferation was suppressed in co-culture assay with DCs 
      treated with RCC CM; proportion CD25+Foxp3+ regulatory T cells were induced to 
      increase. This study suggests that RCC CM can inhibit maturation of DCs and 
      impair its function; moreover, DCs treated with RCC CM induce regulatory T cells 
      increase, thus could contribute RCC escape from antitumor immunity.
FAU - Teng, Lichen
AU  - Teng L
AD  - Department of Urology, Cancer Hospital, Harbin Medical University, No.150 Haping 
      Road, Harbin City, 150086, Heilongjiang Province, China, 
      tenglichen@2008.sina.com.
FAU - Chen, Yongsheng
AU  - Chen Y
FAU - Ding, Dexin
AU  - Ding D
FAU - Dai, Hongshuang
AU  - Dai H
FAU - Liu, Guobin
AU  - Liu G
FAU - Li, Changfu
AU  - Li C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131108
PL  - Netherlands
TA  - Int Urol Nephrol
JT  - International urology and nephrology
JID - 0262521
RN  - 0 (Antigens, CD)
RN  - 0 (B7-1 Antigen)
RN  - 0 (B7-2 Antigen)
RN  - 0 (Culture Media, Conditioned)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Immunoglobulins)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Transforming Growth Factor beta)
RN  - 130068-27-8 (Interleukin-10)
SB  - IM
MH  - Antigens, CD/analysis
MH  - B7-1 Antigen/analysis
MH  - B7-2 Antigen/analysis
MH  - Carcinoma, Renal Cell/*immunology
MH  - Cell Movement
MH  - Cell Proliferation/drug effects
MH  - Culture Media, Conditioned/*pharmacology
MH  - Dendritic Cells/chemistry/*drug effects/*immunology
MH  - Female
MH  - HLA-DR Antigens/analysis
MH  - Humans
MH  - *Immune Tolerance
MH  - Immunoglobulins/analysis
MH  - Interleukin-10/metabolism
MH  - Kidney Neoplasms/*immunology
MH  - Male
MH  - Membrane Glycoproteins/analysis
MH  - Phenotype
MH  - T-Lymphocytes, Regulatory/drug effects
MH  - Transforming Growth Factor beta/metabolism
MH  - Tumor Cells, Cultured
MH  - Tumor Microenvironment
MH  - Up-Regulation/drug effects
MH  - CD83 Antigen
EDAT- 2013/11/10 06:00
MHDA- 2015/01/28 06:00
CRDT- 2013/11/09 06:00
PHST- 2013/08/28 00:00 [received]
PHST- 2013/10/22 00:00 [accepted]
PHST- 2013/11/09 06:00 [entrez]
PHST- 2013/11/10 06:00 [pubmed]
PHST- 2015/01/28 06:00 [medline]
AID - 10.1007/s11255-013-0595-8 [doi]
PST - ppublish
SO  - Int Urol Nephrol. 2014 May;46(5):915-20. doi: 10.1007/s11255-013-0595-8. Epub 
      2013 Nov 8.